Frederic Jacques de Bure
Directeur/Membre du Conseil chez Inpellis, Inc.
Profil
Frederic Jacques de Bure is an Independent Director at Inpellis, Inc. and a General Partner at Nusantara Ventures Singapore Pte Ltd.
He was previously a Non-Affiliated Director at PT Visi Media Asia Tbk.
Mr. de Bure holds an MBA from The University of Chicago and an undergraduate degree from Vassar College.
Postes actifs de Frederic Jacques de Bure
| Sociétés | Poste | Début |
|---|---|---|
| Nusantara Ventures Singapore Pte Ltd. | Corporate Officer/Principal | 01/01/2009 |
Inpellis, Inc.
 Inpellis, Inc. Pharmaceuticals: MajorHealth Technology Inpellis, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing transdermal prescription therapeutics for treating acute and chronic pain resulting from musculoskeletal disorders and peripheral neuropathy. Its products include transdermal ibuprofen for moderate to severe osteoarthritis and transdermal benfotiamine for painful diabetic neuropathy. The company was founded in 2012 and is headquartered in Haddonfield, NJ. | Directeur/Membre du Conseil | 01/01/2015 |
Anciens postes connus de Frederic Jacques de Bure
| Sociétés | Poste | Fin |
|---|---|---|
| PT VISI MEDIA ASIA TBK | Corporate Officer/Principal | 20/03/2012 |
Formation de Frederic Jacques de Bure
| The University of Chicago | Masters Business Admin |
| Vassar College | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PT VISI MEDIA ASIA TBK | Consumer Services |
| Entreprise privées | 2 |
|---|---|
| Nusantara Ventures Singapore Pte Ltd. | |
Inpellis, Inc.
Inpellis, Inc. Pharmaceuticals: MajorHealth Technology Inpellis, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing transdermal prescription therapeutics for treating acute and chronic pain resulting from musculoskeletal disorders and peripheral neuropathy. Its products include transdermal ibuprofen for moderate to severe osteoarthritis and transdermal benfotiamine for painful diabetic neuropathy. The company was founded in 2012 and is headquartered in Haddonfield, NJ. | Health Technology |
